SureSeq NGS products for hematological cancer and solid tumors
SureSeq™ NGS panels have been designed in collaboration with recognised cancer experts to detect key aberrations implicated in a wide range of hematological and solid tumor cancers. More so, you can always modify each panel to what’s relevant to your research with SureSeq myPanel™, our regularly updated, expert-curated library of pre-optimized cancer content. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact requirements.
Our unique panel design coupled with hybridization-based enrichment offers unparalleled coverage completeness and uniformity, allowing accurate detection of low-frequency SNVs and indels, as well as structural aberrations such as ITDs, PTDs, CNVs, LOH and translocations. Combined with our various SureSeq LPK products, SureSeq alleviates the burden of running multiple assays and streamlines your research, delivering comprehensive results using a single NGS workflow.
All SureSeq panels come with Interpret, our powerful and easy-to-use NGS analysis solution providing effortless translation of all your NGS data into meaningful results.
Learn more about our custom NGS panel service
The SureSeq Pan-Myeloid Panel accurately detects SNVs and indels in genes such as CEBPA, JAK2, CALR and MPL, as well as structural variants including FLT3-ITDs and KMT2A-PTDs, providing researchers with a single NGS workflow delivering a comprehensive picture of the genetic make-up of each myeloid sample. The figure (above) shows FLT3-ITDs of various sizes and even regions containing multiple ITDs can be confidently detected. ITD sizes are [A] 174 bp, [B] 225 bp, [C] 195 bp with additional 6 bp, [D] 120 bp and [E] 168 bp with additional 69 bp.
View ProductThe SureSeq CLL + CNV Panel has been designed in collaboration with recognized cancer experts to detect 13 key genes and 5 chromosomal regions implicated in CLL progression. The figure (above) compares SureSeq CLL + CNV Panel data with array data for a 42.7Mb deletion of 11q covering ATM (top) and a 0.6Mb biallelic loss called within a larger ~1Mb single allele deletion in the region covering DLEU2/DLEU1/DLEU7 on chromosome 13q (bottom).
View ProductThe SureSeq Germline Breast Cancer + CNV Panel has been developed to provide comprehensive coverage of 7 key genes implicated in breast and ovarian cancer, including BRCA1 and BRCA2. Detecting SNVs and indels, as well as exon-level to whole gene CNVs, provides researchers with a single NGS workflow to study clinically relevant aberrations and alleviates the burden of running multiple assays. The figure (above) illustrates the excellent coverage uniformity across BRCA1 exons 9, 10 and 11 [A] and BRCA2 exons 9, 10 and 11 [B].
View ProductThe SureSeq Core MPN Panel has been designed in collaboration with recognised cancer experts to detect somatic variants in 3 clinically relevant MPN-associated genes; JAK2, MPL and CALR. The SureSeq Core MPN Panel provides researchers with a single, 1-day NGS workflow for studies into the diagnosis, aetiology and prognosis of MPNs. The figure (above) shows a BCR-ABL translocation reported in Interpret. Split-reads covering both BCR (left panel) and ABL1 (right panel) are detected, indicative of the BCR-ABL gene fusion.
View Product
